A Peptide With a Specific Job
Most research peptides are defined by what they do. SS-31 (elamipretide) is defined by where it goes. It is a tetrapeptide, D-Arg-2',6'-dimethyltyrosine-Lys-Phe-NH2, with an alternating aromatic-cationic structure that lets it pass through cell membranes and accumulate preferentially on the inner mitochondrial membrane, the site of energy production in the cell.
There, it binds cardiolipin, a phospholipid found almost exclusively in that membrane. Cardiolipin anchors the protein complexes of the electron transport chain and keeps them assembled. When cardiolipin is oxidized or displaced, the complexes destabilize, electron transport leaks, and the cell's energy output drops while reactive oxygen species climb. Elamipretide's proposed mechanism is to bind cardiolipin and hold those complexes in working shape.
Why That Matters
Mitochondrial dysfunction shows up across an unusually wide range of conditions, from rare genetic mitochondrial diseases to common aging-related tissue decline. A compound that stabilizes the machinery itself, rather than mopping up free radicals downstream, has been an attractive hypothesis for decades. Elamipretide, developed by Stealth BioTherapeutics, is the furthest-along compound built on it.
The Clinical Trial Record
Elamipretide has one of the more extensive human trial records of any research peptide in its category, and the results are instructive.
Programs have included:
The programs have not produced an FDA approval. Endpoints in the myopathy trials were difficult to move despite measurable biochemical signals, and the company's regulatory path has remained unsettled, with later-stage work in Barth syndrome continuing. For researchers, the pattern is worth internalizing: a compound can demonstrably reach its target and shift measurable biology, and still fail to clear the clinical bar of a meaningful functional endpoint.
Why Researchers Still Follow It
Two reasons. First, the mechanism is unusually well characterized. Elamipretide served as the tool compound that mapped much of what the field knows about cardiolipin's role in electron transport chain assembly, so the mechanistic literature is deep even where the clinical literature is mixed.
Second, the aging-research community's interest in mitochondrial function keeps elamipretide relevant as a reference point. When a paper claims a compound improves mitochondrial function, elamipretide is one of the few compounds with a known, membrane-level mechanism against which those claims can be compared.
Reading the Claims You'll See
Elamipretide gets cited in longevity discussions, sometimes with trial results flattened into "it works" or "it failed." The honest summary is narrower: a well-characterized mechanism, biochemical signals in humans, and functional endpoints that proved stubborn. Anyone evaluating mitochondrial research compounds should treat that distinction as the standard for evidence, in both directions.
Important Note
This article is for educational and research reference purposes only. Elamipretide is an investigational compound with no approved human therapeutic use. Nothing here constitutes medical advice.